Terminated PHASE1/PHASE2 INTERVENTIONAL 9-arm NCT04798027

Study of mRNA Vaccine Formulation Against COVID-19 in Healthy Adults 18 Years of Age and Older (VAW00001)

Immunogenicity and Safety of the First-in-Human SARS-CoV-2 mRNA Vaccine Formulation in Healthy Adults 18 Years of Age and Older

Sponsor: Sanofi Pasteur, a Sanofi Company

Conditions COVID-19

Interventions Placebo (0.9% normal saline) SARS-CoV-2 mRNA vaccine formulation 1 SARS-CoV-2 mRNA vaccine formulation 2 SARS-CoV-2 mRNA vaccine formulation 3

Updated 14 times since 2021 Last updated: Sep 10, 2025 Started: Mar 12, 2021 Primary completion: Jun 27, 2022 Completion: Jun 27, 2022

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Sponsor's decision not to pursue further development of this product given the wide availability of authorized/approved mRNA COVID-19 vaccines

Other terminated trials from Sanofi Pasteur, a Sanofi Company

See all terminations from Sanofi Pasteur, a Sanofi Company

Other COVID-19 trials with similar outcome

Browse all COVID-19 trials

A PHASE1/PHASE2 clinical study on COVID-19, this trial is terminated or withdrawn. The trial is conducted by Sanofi Pasteur, a Sanofi Company and has accumulated 14 data snapshots since 2021. Infectious disease trials contribute critical data for public health response and treatment development.

Status Flow

Change History

14 versions recorded

Oct 2025 — Present [monthly]

Terminated PHASE1/PHASE2
Sep 2025 — Oct 2025 [monthly]

Terminated PHASE1/PHASE2
Sep 2024 — Sep 2025 [monthly]

Terminated PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE1/PHASE2

Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Jan 2024 — Jul 2024 [monthly]

Terminated PHASE1_PHASE2

▶ Show 9 earlier versions

Aug 2023 — Jan 2024 [monthly]

Terminated PHASE1_PHASE2
Sep 2022 — Aug 2023 [monthly]

Terminated PHASE1_PHASE2

Status: Active Not Recruiting → Terminated
Jun 2022 — Sep 2022 [monthly]

Active Not Recruiting PHASE1_PHASE2
Dec 2021 — Jun 2022 [monthly]

Active Not Recruiting PHASE1_PHASE2

Status: Recruiting → Active Not Recruiting
Oct 2021 — Dec 2021 [monthly]

Recruiting PHASE1_PHASE2
Sep 2021 — Oct 2021 [monthly]

Recruiting PHASE1_PHASE2
Jun 2021 — Sep 2021 [monthly]

Recruiting PHASE1_PHASE2
May 2021 — Jun 2021 [monthly]

Recruiting PHASE1_PHASE2
Apr 2021 — May 2021 [monthly]

Recruiting PHASE1_PHASE2

First recorded

Mar 2021

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Sanofi Pasteur, a Sanofi Company

Data source: Sanofi

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Barrio del Centro, Honduras , Belo Horizonte, Brazil , Campo Grande, Brazil , Hollywood, United States , Houston, United States , Iowa City, United States , Kansas City, United States , Knoxville, United States , Melbourne, Australia , Miami, United States and 11 more locations